Christie J Lau (Christine Hann)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 7

Top Topics

Tyrosine Kinase

Circulating Tumor

Top Venues

JCO precision oncology

Proceedings of the National Academy of Sciences of the United States of America

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Conor Klamann, Christie J Lau, Javier Ruiz-Ramírez, Gregory W Schwartz
TooManyCellsInteractive: A visualization tool for dynamic exploration of single-cell data. GigaScience 13 (2024)
Conor Klamann, Christie J Lau, Javier Ruiz-Ramírez, Gregory W Schwartz
TooManyCellsInteractive: A visualization tool for dynamic exploration of single-cell data. GigaScience 13 (2024)
P Mickey Williams, Thomas Forbes, Steven P Lund, Kenneth D Cole, Hua-Jun He, Chris Karlovich, Cloud P Paweletz, Daniel Stetson, Laura M Yee, Dana E Connors, Susan M Keating, Benoit Destenaves, Megan H Cleveland, Christie J Lau, J Carl Barrett, Gary J Kelloff, Robert T McCormack
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health. JCO precision oncology 5 (2021)
Magda Bahcall, Cloud P Paweletz, Yanan Kuang, Luke J Taus, Taebo Sim, Nam Doo Kim, Kshiti H Dholakia, Christie J Lau, Prafulla C Gokhale, Pratik R Chopade, Fangxin Hong, Zihan Wei, Jens Köhler, Paul T Kirschmeier, Jiannan Guo, Sujuan Guo, Stephen Wang, Pasi A Janne
Combination of type I and type II MET tyrosine kinase inhibitors as therapeutic approach to prevent resistance. Molecular cancer therapeutics (2021)
Michael L Cheng, Christie J Lau, Marina S D Milan, Julianna G Supplee, Jonathan W Riess, Penelope A Bradbury, Pasi A Jänne, Geoffrey R Oxnard, Cloud P Paweletz
Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. JCO precision oncology 5 (2021)
Erin M Bertino, Ryan D Gentzler, Sarah Clifford, Jill M Kolesar, Alona Muzikansky, Eric B Haura, Zofia Piotrowska, D Ross Camidge, Thomas E Stinchcombe, Christie J Lau, Jyoti Malhotra, Liza C Villaruz, Cloud P Paweletz, Lynette Sholl, Naoko Takebe, Jeffrey A Moscow, Geoffrey I Shapiro, Pasi A Jänne, Geoffrey R Oxnard
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clinical cancer research : an official journal of the American Association for Cancer Research 27 (6) (2020)
Mohammad Rashidian, Martin W LaFleur, Vincent L Verschoor, Anushka Dongre, Yun Zhang, Thao H Nguyen, Stephen Kolifrath, Amir R Aref, Christie J Lau, Cloud P Paweletz, Xia Bu, Gordon J Freeman, M Inmaculada Barrasa, Robert A Weinberg, Arlene H Sharpe, Hidde L Ploegh
Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proceedings of the National Academy of Sciences of the United States of America 116 (34) (2019)